Clinical trial
TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver…
NCT00077142 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00077142 |
|---|---|
| Title | TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) |
| Official title | Phase I/II Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral TAC-101 in Patients With Advanced Hepatocellular Carcinoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH Taiho Pharmaceutical Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Drug |
| Interventions | TAC-101 |
| Enrollment | 37 |
| Start date | Apr 1, 2001 |
| Primary completion | Jul 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Feb 11, 2004 |
| Last update posted | Oct 31, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: